Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician

Eric D. Hansen, Xiao Wang, Amy A. Case, Igor Puzanov, Tom Smith

Research output: Contribution to journalArticlepeer-review

Abstract

Immune checkpoint inhibitors (ICIs) have opened an exciting chapter in the treatment of patients with advanced cancer. For the palliative care clinician, however, ICIs present several new challenges, including new ways to define treatment success, as well as treatment-related toxicities that differ in nature and timing from traditional chemotherapy. In this article, we review the mechanism of action of ICIs, as well as selected published data supporting the efficacy of ICIs in patients with advanced cancer. In addition, we summarize existing data of ICI toxicity prevalence, patterns of severity, and timing of onset. Finally, we briefly review key principles from published guidelines on the management of ICI toxicities.

Original languageEnglish (US)
Pages (from-to)460-472
Number of pages13
JournalJournal of Pain and Symptom Management
Volume56
Issue number3
DOIs
StatePublished - Sep 2018

Keywords

  • Immunotherapy
  • checkpoint inhibition
  • immune-related adverse events
  • toxicity

ASJC Scopus subject areas

  • Nursing(all)
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician'. Together they form a unique fingerprint.

Cite this